Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA9159 inhalation aerosol in healthy volunteers
NCT06916273Phase 1Completed
- Sponsor
- Anhui Palo Alto Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pa9159 in asthma (5 arms), sponsored by Anhui Palo Alto Pharmaceuticals. Primary endpoints: Adverse Events at 48 hours, Hematology Laboratory Parameters at 48 hours and 8 more. Started Jul 2024; status: completed.
02
Drugs
pa9159
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06916273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916273.